Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence

Jaysón Davidson, Anupama Kumar, Ayan R. Patel, Irene Y. Chen, Atul J. Butte, Travis ZackCancers 2026 · DOI

TL;DR

This study reveals significant disparities in access to CAR-T therapy for multiple myeloma patients within a large academic health system, with treatment location and patient race being key factors. Notably, a substantial portion of eligible patients did not have documented discussions about CAR-T, suggesting systemic barriers beyond clinical appropriateness.

What Problem Does This Paper Address?

Multiple myeloma (MM) is a serious blood cancer, disproportionately affecting Black patients. While CAR-T therapy offers a promising new treatment avenue, its limited availability and specialized nature raise concerns about equitable access. This paper investigates whether factors like where a patient receives care, their demographic background, and disease characteristics influence their likelihood of receiving CAR-T therapy, aiming to identify potential barriers to this advanced treatment.

Methods

The researchers conducted a retrospective cohort study using electronic health records from the University of California Health Data Warehouse (UCHDW). They employed logistic regression to analyze associations between patient demographics, disease characteristics (like ISS stage and CRAB features), treatment location (UC-1, UC-2, UC-3), and CAR-T therapy receipt. A novel aspect of this study was the use of a zero-shot GPT-4 model to analyze clinical notes. This AI approach was used to identify patients who were eligible for CAR-T therapy but had no documented discussion about it, and to categorize the reasons for eligibility determinations.

Datasets

The primary dataset used was the University of California Health Data Warehouse (UCHDW), containing electronic health records for over nine million individuals. This dataset spanned from 2012 to February 2025 and included information on patient demographics, diagnoses, treatments, and clinical notes. The study population specifically comprised 12,360 adult patients diagnosed with MM and treated at a UC facility offering CAR-T administration between January 2021 and January 2025. For the GPT-4 analysis, a subset of 270 UCSF patients with available clinical notes was used.

Key Insights and Ideas

  • Location Matters: CAR-T receipt varied significantly across different UC medical centers, suggesting that the type of facility (e.g., specialty referral vs. comprehensive care) plays a role in access.
  • Race as a Barrier: Even after accounting for disease severity and insurance, Black patients were significantly less likely to receive CAR-T therapy compared to White patients. This points to systemic issues rather than biological differences.
  • The "Undiscussed" Eligible Patient: A striking finding is that a notable percentage of patients deemed eligible for CAR-T therapy had no recorded discussion about it with their providers. This highlights potential gaps in communication, referral pathways, or patient engagement.
  • Disease Severity is a Factor: Patients with more severe disease (indicated by a higher number of CRAB features) were more likely to receive CAR-T, suggesting that while access is an issue, the urgency of the disease can drive treatment decisions.
  • AI for Deeper Understanding: The use of GPT-4 to analyze clinical notes provided a unique window into undocumented aspects of care, such as the absence of CAR-T discussions for eligible patients.

Key Results

  • Out of 12,360 MM patients, only 320 (2.6%) received CAR-T therapy.
  • Black or African American patients had significantly lower odds of receiving CAR-T therapy compared to White patients (OR = 0.33).
  • Patients treated at UC-3 had lower odds of receiving CAR-T compared to UC-1 (OR = 0.42).
  • Among 270 UCSF patients assessed for eligibility, those identifying as Other Pacific Islander had the highest proportion (50%) of eligibility without a documented CAR-T discussion, followed by Black or African American patients (4.2%) and Asian patients (3.2%).
  • Patients with a higher number of CRAB features had increased odds of receiving CAR-T therapy (OR = 1.43).

Limitations and Future Work

The authors acknowledge several limitations:

  • Temporal Bias: Changes in CAR-T indications and clinical practice between 2021 and 2025 could introduce temporal bias.
  • Data Completeness: ISS staging was unavailable for some patients due to missing lab data, limiting the use of the revised ISS. CRAB features reflect clinical manifestations, not comprehensive biological risk.
  • Socioeconomic Measurement: The Area Deprivation Index (ADI) is a neighborhood-level measure and may not fully capture individual socioeconomic barriers.
  • Clinical Notes Analysis: The GPT-4 analysis was limited to UCSF clinical notes and could not account for undocumented decisions, patient preferences, or unmeasured barriers.
  • Direct Access Measures: The study evaluated documented receipt, not direct measures of access.

Future work should incorporate individual-level social determinants of health, detailed referral patterns, and a broader clinical context to fully understand the drivers of CAR-T utilization and promote equitable delivery of advanced therapies. Further investigation into why Hispanic or Latino patients had higher odds of receiving CAR-T compared to White patients is also warranted, as this contrasts with some prior reports.

Summary updated

Abstract

<b>Importance</b>: Multiple myeloma (MM) is the second most common hematologic malignancy in the U.S., with a higher incidence among Black patients than White patients. Chimeric antigen receptor T-cell (CAR-T) therapies show clinical promise, but their limited availability raises concerns about access. <b>Objective</b>: To examine associations between disease characteristics, treatment location, and patient demographics with receipt of CAR-T therapy among patients with MM. <b>Design</b>: Retrospective cohort study using electronic health record data from the University of California Health Data Warehouse (UCHDW) between January 2021 and January 2025. <b>Setting</b>: Six academic health centers and twelve affiliated hospitals within the UCHDW. <b>Participants</b>: A population-based cohort of 12,360 adult patients diagnosed with MM and treated at a University of California facility offering CAR-T administration. Analyses were conducted from February 2025 to March 2025. <b>Exposures</b>: Receipt of multiple cancer therapies following MM diagnosis. <b>Main Outcomes and Measures</b>: Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between disease characteristics, treatment locations, and patient demographics with receipt of CAR-T therapy. A zero-shot GPT-4 inference model was applied to UCSF clinical notes to assess whether CAR-T therapy was discussed, determine documented eligibility, and classify rationale for eligibility determinations. <b>Results</b>: Among 12,360 patients with MM (mean age, 68.5 years; 51.6% male), 320 (2.6%) received CAR-T therapy. Disease characteristics at diagnosis, measured by the International Staging System (ISS), was distributed as follows: Stage I (65.3%), Stage II (24.4%), Stage III (2.8%), and Unknown (7.5%). Patients treated at UC-1 (49.3%), and UC-2 (50.0%) were more frequently diagnosed with ISS Stage II, whereas patients treated at UC-3 (55.5%) were more frequently diagnosed with ISS Stage I. Our model showed that patients identifying as Black or African American had lower odds of receiving CAR-T therapy compared with White patients (OR, 0.33; [95% CI, 0.17-0.62]). Patients treated at UC-3 also had lower odds of receiving CAR-T therapy compared with UC-1 (OR, 0.42; [95% CI, 0.30-0.59]). Among 270 UCSF patients assessed for CAR-T eligibility using clinical notes, the proportion of patients deemed eligible without documented CAR-T discussions was highest among those identifying as Other Pacific Islander (50%), followed by Black or African American (4.2%), Asian (3.2%), and White patients (0.6%). <b>Conclusions and Relevance</b>: Within a large academic health system, receipt of CAR-T therapy varied by treatment location and patient-reported race. A subset of patients with documented eligibility lacked recorded discussions of CAR-T therapy, suggesting potential differences in referral, documentation, or care pathways influencing observed treatment patterns.
BibTeX
@inproceedings{davidson2026investigating,
  author = {Jaysón Davidson and Anupama Kumar and Ayan R. Patel and Irene Y. Chen and Atul J. Butte and Travis Zack},
  title = {{Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence}},
  booktitle = {Cancers},
  year = {2026},
  doi = {10.3390/cancers18040669},
}
Figure